BOTHELL, Wash.--(BUSINESS WIRE)--
Iverson Genetic Diagnostics, Inc. announced today a partnership agreement with Vanderbilt University under which Iverson receives global exclusive commercialization rights for molecular diagnostics that will help physicians to assess breast cancer risk in women considering hormone replacement therapy during menopause. Research suggests that estrogen metabolites represent one of several determinants of the risk of breast cancer. Specific enzymes regulate the biochemical pathways associated with the metabolism of estrogen. Corresponding genes code for the synthesis of these enzymes. Mutations of these genes are common and have been shown in the work of Fritz Parl, M.D., Ph.D., Philip Crooke, Ph.D., William Dupont, Ph.D., and others to be associated with an increased risk of cancer.
Dr. Sujatha Reddy, M.D., OB/GYN at Premier Care for Women in Atlanta and Medical Correspondent for WXIA, a NBC affiliate in Atlanta, said, “I think I will use this test in my practice for patients who are trying to decide if they should stay on hormone replacement therapy (HRT). If you break down estrogen well, you may be at lower risk for breast cancer and then choose to continue your hormones. We can give people a more individualized therapy based on their own genetic makeup.”
Leroy Hood, M.D., Ph.D., co-founder of the Institute for Systems Biology and a member of Iverson Genetic Diagnostics’ Board of Directors, commented, “The importance of finding gene variants that affect the metabolism of drugs and hormones--hence causing disease--is incredibly important for personalized medicine. This venture between Iverson and Vanderbilt is a wonderful example of a diagnostic test that could significantly improve the health of relevant patients.”
Dean Sproles, CEO of Iverson Genetic Diagnostics, Inc., stated, “We are very pleased to collaborate with Vanderbilt University on this product and look forward to including the new e-Metab GenoSTATTM test in the Women’s Health segment of Iverson’s Physician’s LogicTM portfolio later this year. We are considering additional opportunities to partner with Vanderbilt University in the areas of Women’s Health and Autoimmunity.”
About Iverson Genetic Diagnostics, Inc.
Iverson Genetic Diagnostics, Inc. is a Nevada C corporation with administrative headquarters in Bothell, Washington, and production headquarters in Charleston, South Carolina. Iverson is establishing a recognizable global brand for providing trusted genetic tests and testing services for the emerging market of individualized medicine and genetics-based molecular diagnostics. The company’s mission is to improve patient outcomes through personalized care. Iverson is a fully credentialed laboratory service company focused on providing results within 24 hours for hospitals and physicians. Iverson’s patented technology, Physician’s LogicTM, is our healthcare information resource developed to deploy test results to providers and integrate with various electronic medical record systems in a HIPAA-compliant environment.
Go here to see the original:
Iverson Genetic Diagnostics, Inc. Announces a Strategic Partnership with Vanderbilt University for the Development and ...